The Controlling Nutritional Status (CONUT) score is a novel nutritional index that integrates the serum albumin level, peripheral blood lymphocyte count, and total cholesterol level. This retrospective study explores its prognostic significance in patients undergoing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). We included 436 patients who underwent CRS-HIPEC, categorized into low (0–3) and high (4–12) CONUT score groups, and performed logistic regression analysis to predict one-year mortality and postoperative morbidity. Our findings revealed that high CONUT scores correlate with increased one-year mortality (47.1% vs. 20.3%,p< 0.001) and morbidity (39.2% vs. 18.2%,p< 0.001) compared to low CONUT scores. Multivariable regression analysis confirmed high CONUT scores as independent predictors of one-year mortality (odds ratio: 2.253, 95% CI: 1.014–5.005,p= 0.046) and postoperative morbidity (odds ratio: 2.201, 95% CI: 1.066–4.547,p= 0.033). These results underscore the CONUT score’s effectiveness as an independent marker for evaluating risks associated with CRS-HIPEC, emphasizing its potential to improve risk stratification.
控制营养状态（CONUT）评分是一种新型营养指标，整合了血清白蛋白水平、外周血淋巴细胞计数和总胆固醇水平。本回顾性研究探讨了其在接受肿瘤细胞减灭术联合腹腔热灌注化疗（CRS-HIPEC）患者中的预后意义。研究纳入436例接受CRS-HIPEC治疗的患者，将其分为低分组（0–3分）和高分组（4–12分），并通过逻辑回归分析预测一年死亡率和术后并发症发生率。结果显示，与低CONUT评分组相比，高CONUT评分组患者的一年死亡率（47.1% vs. 20.3%，p<0.001）和并发症发生率（39.2% vs. 18.2%，p<0.001）显著升高。多变量回归分析证实，高CONUT评分是一年死亡率（比值比：2.253，95%置信区间：1.014–5.005，p=0.046）和术后并发症发生率（比值比：2.201，95%置信区间：1.066–4.547，p=0.033）的独立预测因子。这些结果凸显了CONUT评分作为评估CRS-HIPEC相关风险的独立标志物的有效性，并强调了其在改善风险分层方面的潜在价值。
肿瘤(癌症)患者之家